21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
19:44 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Complete response letter for Motif's antibiotic

FDA issued a complete response letter to an NDA for iclaprim (MTF-100) from Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) to treat acute bacterial skin and skin structure infections (ABSSSIs). Motif said FDA indicated additional liver toxicity...
20:26 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Blindness Mouse studies identified a LIF-based fusion protein that could help treat blindness. The fusion protein consists of human LIF fused to bacterial dihydrofolate reductase (DHFR), which is stabilized by the antibiotic Primsol trimethoprim....
17:50 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria In vitro , cell culture and mouse studies identified asparagine ethylenediamine-based inhibitors of Plasmodium falciparum proteasome subunit β type 5 that could help treat malarial infection. Screening of a library of tool compound...
03:32 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

Motif's antibiotic gets Priority Review

Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) said FDA accepted and granted Priority Review to an NDA for iclaprim (MTF-100) to treat acute bacterial skin and skin structure infections (ABSSSIs). Its PDUFA date is Feb. 13, 2019....
17:32 , Aug 14, 2018 |  BC Extra  |  Company News

Motif's antibiotic gets Priority Review

Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) said FDA accepted and granted Priority Review to an NDA for iclaprim (MTF-100) to treat acute bacterial skin and skin structure infections (ABSSSIs). Its PDUFA date is Feb. 13, 2019....
17:21 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Motif delays NDA for iclaprim in ABSSSIs

Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) said it will delay submitting its NDA for iclaprim (MTF-100) to FDA until next quarter. The company had hoped to submit the NDA this quarter seeking the antibiotic's approval to...
23:12 , Mar 20, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; high throughput screening A high throughput, comparative metabolomics screen could predict MOAs of antimicrobial compounds. The method involves four steps: treating bacterial culture with a library of reference antimicrobials; using high throughput,...
17:45 , Mar 20, 2018 |  BC Extra  |  Company News

Motif delays NDA for iclaprim in ABSSSIs

Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) said it will delay submitting its NDA for iclaprim (MTF-100) to FDA until next quarter. The company had hoped to submit the NDA this quarter seeking the antibiotic's approval to...